Search PubMed⌕ Search

Biomedical subjects

M Laakso

Publications and source records attributed to M Laakso.

At least 253 records · Page 14Linked to original sources
PubMed1994

Impact of risk factors on limb salvage after angioplasty in chronic critical lower limb ischemia. A prospective trial.

The impact of various general risk factors on long-term results of percutaneous transluminal angioplasty (PTA) in chronic critical lower limb ischemia is poorly known. In a prospective trial 209 PTAs were performed in 103 consecutive patients with 117 limbs with chronic critical ischemia. The general risk factors that might affect the long-term results of PTA in this patient population were reviewed. Among the factors that showed no statistical significance were all associated diseases, smoking history, and medication used. Of the various clinical chemical parameters, only serum high density lipoprotein (S-HDL) cholesterol and plasma fibrinogen had a statistically significant influence on limb salvage rate in Kaplan-Meier analysis. These parameters proved to be significant determinants also in Cox multiple regression analysis when PTA target-vessel-related parameters (peripheral runoff and number of diseased vessels) were also included in the model. Cox model predicts up to 86% one-year limb salvage for the "good" group (one to five diseased lower limb vessels/limb, S-HDL cholesterol > 0.78 mmol/L, plasma fibrinogen < 4.9 g/L).

Adult↗
PubMed1994

Insulin resistance, body fat distribution, and sex hormones in men.

Although many studies have suggested that increased androgenicity is associated with insulin resistance and hyperinsulinemia in both pre- and postmenopausal women, relatively few data are available on this relationship in men. We examined the association of body mass index (BMI), waist-to-hip ratio (WHR), sex hormone-binding globulin (SHBG), total and free testosterone, dehydroepiandrosterone sulfate (DHEA-SO4), and estradiol with insulin concentrations and whole-body glucose disposal in 87 men from a population-based study in Kuopio, Finland. BMI was significantly correlated with fasting insulin (r = 0.46), total whole-body glucose disposal (r = -0.30), glucose oxidation (r = -0.21), and nonoxidative glucose disposal (r = -0.25). WHR also was significantly associated with fasting insulin (r = 0.61), total whole-body glucose disposal (r = -0.54), glucose oxidation (r = -0.23), and nonoxidative whole-body glucose disposal (r = -0.50). SHBG and total and free testosterone were significantly associated with insulin concentrations and total and nonoxidative glucose disposal but not with glucose oxidation. DHEA-SO4 and estradiol were not associated with insulin, glucose concentrations, or whole-body glucose disposal in univariate analysis. In multivariate analysis, total whole-body glucose disposal was associated negatively with WHR and positively associated with total testosterone and SHBG; nonoxidative whole-body glucose disposal was associated negatively with WHR and positively associated with total and free testosterone. Glucose oxidation was significantly associated only with WHR. In conclusion, higher WHR and lower testosterone were strongly associated with a decrease in total and nonoxidative whole-body glucose disposal in men.

Adipose Tissue↗
PubMed1994

Isolated low HDL cholesterol. An insulin-resistant state.

High levels of very-low-density lipoprotein (VLDL) triglycerides (TGs) and low levels of high-density lipoprotein (HDL) cholesterol have been found to be associated with insulin resistance. However, direct evidence that patients with isolated low HDL cholesterol are insulin resistant is still lacking. Therefore, we investigated the degree of insulin resistance and intracellular metabolism of glucose by the euglycemic glucose clamp technique and indirect calorimetry in three groups of subjects with normal glucose tolerance: 17 male control subjects with normolipidemia, 12 male patients with isolated low HDL cholesterol (low HDL group), and 10 male patients with low HDL cholesterol and hypertriglyceridemia (low HDL/high TG group). Fasting, 1-h, and 2-h glucose levels did not differ between the groups in an oral glucose tolerance test (OGTT). In contrast, insulin levels during an OGTT were significantly higher in the low HDL group than in the control group (fasting insulin: 85 +/- 11 vs. 50 +/- 6 pM, P = 0.005; 1-h insulin: 622 +/- 92 vs. 394 +/- 64 pM, P = 0.004; and 2-h insulin: 343 +/- 73 vs. 194 +/- 40 pM, P = 0.006). Similarly, insulin levels were also higher in the low HDL/high TG group than in the control group (fasting insulin: 82 +/- 14 pM, P = 0.037; 1-h insulin: 795 +/- 179 pM, P = 0.063; and 2-h insulin: 488 +/- 145 pM, P = 0.040).(ABSTRACT TRUNCATED AT 250 WORDS)

Blood Glucose↗
PubMed1994

Microalbuminuria precedes the development of NIDDM.

Several studies have indicated that insulin resistance, elevated blood pressure (BP), and dyslipidemia precede the onset of non-insulin-dependent diabetes mellitus (NIDDM). Little data, however, exist on the presence of renal disease in prediabetic subjects. We measured albumin excretion in a cross-sectional population study in subjects 65-74 years of age living in eastern Finland in relation to the risk of developing diabetes 3.5 years later. The prevalence of microalbuminuria (urinary albumin-to-urinary creatinine ratio > or = 2 mg/mmol) was 1.3-, 1.8-, and 2.0-fold higher among subjects with impaired glucose tolerance (n = 242), newly diagnosed NIDDM subjects (n = 92), and previously diagnosed NIDDM subjects (n = 136), respectively, compared with subjects with normal glucose tolerance (n = 826). Nondiabetic subjects with microalbuminuria had multiple abnormalities in cardiovascular risk factors including elevated BP, high triglyceride concentration, high insulin concentration, and a low high-density lipoprotein cholesterol concentration, a cluster of risk factors typical for prediabetic individuals. The relationship between microalbuminuria and the incidence of NIDDM over the 3.5-year follow-up was studied in 891 subjects who were free of diabetes at baseline. Converters to diabetes (n = 69) had a higher prevalence of hypertension (68.1 vs. 54.4%, P < 0.05) and a higher prevalence of microalbuminuria (43.5 vs. 30.4%, P < 0.05) than nonconverters (n = 822). In logistic regression analysis, microalbuminuria predicted the development of NIDDM independently of BP level.(ABSTRACT TRUNCATED AT 250 WORDS)

Age Factors↗
PubMed1994

NIDDM and its metabolic control predict coronary heart disease in elderly subjects.

The aim of this study was to evaluate whether noninsulin-dependent diabetes (NIDDM) and its metabolic control and duration predict coronary heart disease (CHD) events during a 3.5-year follow-up in a randomly selected Finnish population sample 65-74 years of age at baseline. Of 1,298 subjects participating in the baseline study, 1,069 were nondiabetic and 229 had NIDDM. During the follow-up, 3.4% of nondiabetic and 14.8% of NIDDM subjects died from CHD or had a nonfatal myocardial infarction (MI). The impact of NIDDM on CHD mortality and morbidity was more marked in women than in men. Odds ratios (ORs) and their 95% confidence intervals for CHD death and nonfatal MI in women with NIDDM compared with women with normal glucose tolerance were 11.7 (3.8-36.4) and 4.7 (3.6-6.1). In men, the corresponding ORs were 0.43 (0.1-1.9) and 1.4 (0.6-3.2). In multiple logistic regression analyses including all study subjects, NIDDM (P < 0.01), male sex (P < 0.05), and previous MI (P < 0.01) predicted CHD death (n = 45). NIDDM (P < 0.01), male sex (P < 0.05), previous MI (P < 0.05), current smoking (P < 0.001), systolic blood pressure (P < 0.001), and low high-density lipoprotein cholesterol (P < 0.01) predicted all CHD events (CHD death or nonfatal MI) (n = 107). In NIDDM subjects, only glycated hemoglobin A1c (GHbA1c) at baseline (P < 0.01) and duration of diabetes (P < 0.05) predicted CHD death (n = 15) and all CHD events (n = 33). There was a significant increase in the risk of CHD death and all CHD events in NIDDM subjects with GHbA1c levels higher than 7.0% compared with diabetic subjects with lower GHbA1c (ORs 4.3 [1.1-16.7] and 2.2 [1.0-5.1]). In conclusion, NIDDM and its metabolic control and the duration of diabetes are important predictors of CHD in elderly subjects, particularly in women.

Aged↗
PubMed1994

Prevalence of isthmic lumbar spondylolisthesis in nondiabetic subjects and NIDDM patients.

OBJECTIVE: To compare the prevalence of lumbar spondylolytic spondylolisthesis (LSS) in nondiabetic and diabetic subjects. RESEARCH DESIGN AND METHODS: A cross-sectional study of 1,147 randomly selected nondiabetic subjects and 892 non-insulin-dependent diabetes mellitus (NIDDM) patients, 45-64 years of age. LSS was diagnosed radiographically using a lateral view of the lumbosacral spine. RESULTS: No significant difference was seen in the prevalence of LSS between nondiabetic (6.0%) and diabetic (5.7%) subjects. LSS was more frequent in nondiabetic men (7.7%) than in nondiabetic women (4.6%; P = 0.026), whereas diabetic patients showed no significant sex difference in the prevalence of LSS (men 5.6% and women 5.9%). CONCLUSIONS: NIDDM does not predispose one to lumbar spondylolisthesis. However, diabetes seems to abolish the sex difference in the prevalence of LSS observed in nondiabetic populations.

Cross-Sectional Studies↗
PubMed1994

Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects.

BACKGROUND: In several studies hypertension has been shown to be associated with an increased incidence of non-insulin-dependent diabetes mellitus (NIDDM). This may be due to hypertension itself or to the deleterious effects of some antihypertensive agents on glucose tolerance and insulin sensitivity. METHODS: We examined the 3.5-year incidence of diabetes mellitus in relation to hypertension and antihypertensive medication in a population-based study of elderly subjects (n = 805) aged 65-74 years in Kuopio, Finland. RESULTS: Of the subjects studied, 60% had hypertension at baseline and 50% of the hypertensive subjects were on drug therapy at baseline. Hypertensive subjects had a significantly higher incidence of NIDDM than non-hypertensive subjects. However, after adjustment for age, body mass index, waist: hip ratio, sex, and fasting glucose and insulin levels, the increased risk of NIDDM in hypertensive subjects was no longer statistically significant. Subjects with high blood pressure (> or = 160/95 mmHg) at the baseline examination who were not taking beta-blockers or diuretic medication had a 1.56-fold increased risk of developing NIDDM, whereas subjects with hypertension who were taking those agents had a 1.88-fold risk of developing NIDDM compared with subjects with normal blood pressure. The risk of developing NIDDM was accompanied by elevated fasting insulin levels. After adjustment for age, sex, body mass index, waist:hip ratio, and fasting glucose and insulin levels, hypertensive subjects taking diuretics or beta-blockers, or both, still had a 1.56-fold increased risk of developing NIDDM relative to normotensive subjects. Hypertensive subjects taking diuretics or beta-blockers, or both, had a significantly higher incidence of NIDDM than hypertensive subjects not on pharmacological therapy. However, after adjustment for 2-h glucose and insulin concentrations, the incidence of NIDDM did not differ between the hypertensive subjects. CONCLUSION: The data presented suggest that the increased risk of NIDDM in hypertensive subjects taking beta-blockers or diuretics, or both, is explained at least partly by metabolic disturbances related to drug therapy.

Adrenergic beta-Antagonists↗
PubMed1993

Human hexokinase II: sequence and homology to other hexokinases.

The amino acid sequence of human hexokinase II was deduced from the sequence of cDNA clones isolated from a skeletal muscle library. An open reading frame of 2751 bases encodes a protein of 917 amino acids. The deduced amino acid sequence has 94% identity with rat hexokinase II but only 72% identity with human hexokinase type I. In addition to hexokinase II clones, the human skeletal muscle cDNA library contained at least an equal number of clones of hexokinase I, the isoform reported to be typically found in kidney and brain. Genetic variation in hexokinase II could underlie insulin resistance in peripheral tissues and cause non-insulin-dependent diabetes mellitus. The availability of this sequence would facilitate investigating the role of mutations in the HKII gene in the etiology of this disease.

Adolescent↗
PubMed1993

High plasma insulin level associated with coronary heart disease in the elderly.

The relation between plasma insulin level and the prevalence of coronary heart disease was studied in a representative nondiabetic population sample of 396 men and 673 women aged 65-74 years in Kuopio, eastern Finland, in 1986-1988. No association between plasma insulin levels and the prevalence of previous myocardial infarction was seen, except for a positive relation between 2-hour insulin level and myocardial infarction in women (4.1, 4.1, and 11.9%, p < 0.01; insulin quintiles I+II, III+IV, and V, respectively). However, the prevalence of ischemic electrocardiographic changes increased by quintiles of fasting plasma insulin (not significant) and 2-hour plasma insulin (39.8, 50.6, and 59.5% in men, p < 0.01; 35.9, 39.0, and 53.0% in women, p < 0.01). Furthermore, the prevalence of angina pectoris increased by fasting insulin (19.3, 19.0, and 33.8%, in men, p < 0.05; not significant in women) and 2-hour insulin quintiles (11.2, 28.8, and 30.4% in men, p < 0.001; 17.0, 17.8, and 28.4% in women, p < 0.05). There was a marked clustering of risk factors, including high total triglyceride levels, low high density lipoprotein cholesterol levels, and hypertension in subjects in the highest insulin quintiles. The association between insulin levels and coronary heart disease, except for myocardial infarction in women, diminished in multivariate analyses. In conclusion, hyperinsulinemia was related to an increased prevalence of coronary heart disease in elderly subjects which may be due to in part to adverse alterations in other risk factors associated with hyperinsulinemia.

Aged↗
PubMed1993

How good a marker is insulin level for insulin resistance?

Epidemiologic studies have correlated fasting and postload insulin levels with the risk of coronary heart disease, assuming that insulin levels are reliable markers of insulin resistance. However, this assumption has not been systematically studied. The author measured insulin response to an oral glucose load and quantitated insulin resistance using the euglycemic hyperinsulinemic clamp technique to evaluate the correlation between insulin level and the degree of insulin resistance in individuals with varying degrees of glucose tolerance. Subjects were randomly selected from previous population studies done in 1987-1989 at the Department of Medicine of the University of Kuopio in east Finland. Altogether, 50 subjects with normal glucose tolerance, 28 with impaired glucose tolerance, and 54 with non-insulin-dependent diabetes mellitus were studied. Correlations of insulin resistance (whole-body glucose uptake in clamp studies) with fasting or postload insulin levels were remarkably consistent, ranging from -0.58 to -0.74 (p < 0.01) in subjects with normoglycemia. In contrast, corresponding correlations were substantially weaker in subjects with impaired glucose tolerance and non-insulin-dependent diabetes. Among these subjects, only the fasting insulin level correlated significantly with insulin resistance (-0.47, p < 0.05 and -0.48, p < 0.01, respectively). The authors conclude that in population studies, only the fasting insulin level should be used as a marker of insulin resistance, particularly in subjects with abnormal glucose tolerance.

Aged↗
PubMed1993

Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event.

OBJECTIVE: A secondary subgroup analysis of the European Stroke Prevention Study of the effect of antiplatelet medication on the risk of myocardial infarction. DESIGN AND SETTING: A randomized, double-blind placebo-controlled study with two parallel treatment groups (dipyridamole plus aspirin and placebo). Sixteen centers from six countries participated in the study. PATIENTS: A total of 2500 patients who had had one or more transient ischemic attacks or cerebral infarctions participated. INTERVENTION: Combination therapy with dipyridamole (75 mg three times a day) and aspirin (330 mg three times a day) was compared with placebo during 24 months' follow-up. OUTCOME MEASURES: Prevention of fatal and nonfatal myocardial infarction. RESULTS: A total of 105 myocardial infarctions occurred in the intention-to-treat analysis and 76 occurred in the explanatory analysis. The overall risk reduction of myocardial infarction with the study drugs was approximately 40% in both statistical analyses, but the result was statistically significant only in the intention-to-treat analysis. Therapeutic efficacy was better among male patients, patients younger than 65 years, and patients with hypertension. CONCLUSION: Combination therapy with dipyridamole and aspirin reduces not only the risk of cerebrovascular ischemic events but also the risk of myocardial infarction.

Aged↗
PubMed1993

Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects.

Risk factors measured in a cross-sectional study in subjects aged 65-74 years living in eastern Finland were correlated with the risk of developing diabetes 3.5 years later. Sixty-nine of 892 initially non-diabetic subjects developed diabetes during the follow-up. Subjects who subsequently developed diabetes had multiple adverse changes in risk factor levels before the diagnosis of diabetes. Subjects who developed diabetes had higher body mass index and waist-hip ratio as well as higher levels of fasting and 2-h plasma glucose and insulin and higher prevalence of family history of diabetes than those who remained healthy. Furthermore, prevalence of hypertension and levels of diastolic blood pressure and total triglycerides were higher and HDL cholesterol lower among subjects who developed diabetes than among those who remained healthy. The highest risk of developing diabetes was associated with impaired glucose tolerance (World Health Organisation criteria) (odds ratio = 9.8, 95% confidence interval = 6.1-5.8). The risk of developing diabetes was 3.7 (3.2-6.1) among subjects in the highest quartile of 2-h insulin distribution, 3.5 (2.0-6.1) in those with triglycerides greater than 2.5 mmol/l, 2.7 (1.5-4.6) in those with waist-hip ratio greater than 1.0, 2.5 (1.5-4.4) in those with HDL cholesterol less than 1.0 mmol/l, 2.1 (1.2-3.6) in those with body mass index greater than 30 kg/m2, 1.9 (1.1-3.3) among those in the highest quartile of fasting insulin distribution, 1.8 (1.0-3.1) in those having hypertension, and 1.7 (1.0-2.9) in those with a family history of diabetes.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1993

Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus.

The role of apoliprotein E (apo E) in modulating the susceptibility of individuals with non-insulin-dependent diabetes mellitus (NIDDM) to atherosclerotic vascular disease was studied in 143 male and 128 female patients with NIDDM. The data show that the apolipoprotein phenotype E2 somehow protects from macrovascular complications in NIDDM both in men and women. E2 also tends to protect from microvascular complications. In contrast, apo E phenotypes E4/4 and E4/3 tend to increase the risk for macroangiopathy in NIDDM patients. The lower prevalence of macroangiopathy in the subjects with E2 was associated with lower plasma total and LDL cholesterol concentrations and low plasma lipoprotein(a) levels. Overall, this study demonstrates the role of the apo E phenotype to modulate the risk for diabetic complications in patients with NIDDM. The confirmation of the association of apo E polymorphism with diabetic complications warrants, however, long-term follow-up studies.

Apolipoproteins E↗
PubMed1993

Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus.

To determine whether albuminuria is associated with insulin resistance in patients with type II (non-insulin-dependent) diabetes mellitus, we performed hyperinsulinemic (40 mU/m2/min) euglycemic clamp studies in patients with a urinary albumin excretion (UAE) rate greater than 30 mg/24 h and in patients with a UAE less than 30 mg/24 h. The UAE-positive group (n = 22) did not differ significantly from the UAE-negative group (n = 18) with respect to age, sex, treatment of diabetes, body mass index, fasting or postload blood glucose or plasma insulin levels, blood pressure, or known duration of diabetes. The mean glucose disposal rate (GDR) was significantly lower in the UAE-positive group than in the UAE-negative group (3.44 +/- 0.29 v 4.75 +/- 0.52 mg/kg/min, P < .05). When patients with hypertension were excluded, GDR was still markedly lower in the UAE-positive group than in the UAE-negative group (3.89 +/- 0.54 v 6.68 +/- 0.71 mg/kg/min, P = .01). The difference between groups persisted even after adjustment for body mass index, sex, and hypertension (ANCOVA; P < .05). These results indicate that the presence of microalbuminuria is associated with impaired insulin action in patients with type II diabetes mellitus.

Albuminuria↗
PubMed1993

Abnormalities in left ventricular diastolic function in male patients with rheumatoid arthritis without clinically evident cardiovascular disease.

Epidemiological studies have suggested that patients with rheumatoid arthritis (RA) have increased mortality due to cardiovascular disease. We studied cardiac performance in 12 asymptomatic male patients with RA and 14 control subjects to elucidate early disturbances in cardiac function. In echocardiography, isovolumic relaxation time was longer (64 +/- 6 vs. 49 +/- 3 ms, mean +/- SEM, P = 0.010) and peak filling rate (134 +/- 10 vs. 159 +/- 6 mm s-1, P = 0.015) lower in patients with RA than in control subjects, reflecting an impairment in left ventricular diastolic function. Left ventricular systolic function assessed by radionuclide angiocardiography at rest and during exercise was similar in both groups. There were no differences between the patients with RA and control subjects in the heart rate, systolic blood pressure and oxygen uptake during peak exercise. Left ventricular diastolic function is impaired in spite of normal left ventricular systolic function in patients with RA without clinically evident cardiovascular disease and this may contribute to the excess of cardiovascular mortality in patients with RA.

Adult↗
PubMed1993

European Stroke Prevention Study (ESPS): antithrombotic therapy is also effective in the elderly.

The ESPS was a multicenter study comparing the effect of the combination of dipyridamole 75 mg and acetylsalicylic acid 330 mg t.i.d. to placebo in 2500 patients (intention-to-treat analysis) and 1861 patients (explanatory analysis) in the secondary prevention of stroke or death after one or more attacks of TIA, RIND or stroke of atherothrombotic origin. End-point reduction was evaluated in two age groups, those not older than 65 years (1358 patients) and those who were older than 65 years (1142 patients). End-point reduction was significantly greater in patients with active therapy than in the placebo group in both age groups. Subgroup analyses with stroke as an end-point indicated that younger patients with TIA (< or = 65 years) had lower risk of stroke than those > 65 years or patients with stroke. The overall risk reduction was best in TIA patients > 65 years of age. The risk reduction with study medication was 40-50% in both sexes and in both age groups. Thus, age of the patient does not influence the efficacy of antithrombotic therapy. However, since these results are obtained from a secondary analysis of a subgroup of patients, the results may need confirmation by further studies.

Actuarial Analysis↗